Sheri Mullen
Sheri Mullen is vice president, immunology and rare disease business unit, US pharmaceuticals for GlaxoSmithKline. She was appointed to her current position in Sept. 2010 to build the immunology and rare diseases team, a new specialty business for GSK. She has commercial responsibility for leading, developing and managing the strategic performance of the business. A dedicated professional who has more than 23 years of commercial experience, Mullen joined GlaxoSmithKline in 1990 as a sales representative and held various positions of increasing responsibility in sales, marketing and operations. Prior to heading the I&RD team, she was the VP of sales for the oncology business where she helped successfully launch several new medicines and transform the oncology commercial model. @GSKUS